The Value of Percutaneous Contrast‐Enhanced Ultrasound in Sentinel Lymph Node Identification, Metastatic Status and Burden Diagnosis in Early Breast Cancer
Journal of Ultrasound in Medicine · 2024-02 · 43 (2) · 293-303
DOI: 10.1002/jum.16359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ultrasound in Medicine, online erschienen am 24.10.2023. Verfasst von Wenjing Pang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ultrasound Medical Center, Lanzhou University Second Hospital, Lanzhou, China. Hauptthemen laut MEDLINE: Sentinel Lymph Node, Breast Neoplasms, Lymphadenopathy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
The aim of this study was to evaluate the value of percutaneous contrast‐enhanced ultrasound (PCEUS) in the identification and characterization of sentinel lymph node (SLN).
Methods
A total of 102 breast cancer patients were collected and underwent preoperative PCEUS, which was used to identify SLN and lymphatic drainage. SLNs were classified into 4 enhancement patterns, including 6 subtypes: homogeneous (I), featured inhomogeneous (II) including inhomogeneous hypoenhancement (IIa) and annular or semi‐annular enhancement (IIb), focal filling defect (III) including filling defect area < 50% (IIIa) and filling defect area ≥ 50% (IIIb), and no enhancement (IV). The enhancement patterns of SLNs were compared with the final pathological diagnosis.
Results
The identification rate of SLNs using PCEUS was 100% (102/102); the rate of identification of LCs was 100% (102/102), and the coincidence rate was 98.0% (100/102). Four lymphatic drainage patterns (LDPs) including 5 subtypes were found: single LC/single SLN(74.5%), multiple LCs/ single SLN (13.7%) including 2 subtypes:2 LCs/1 SLN and 3 LCs/1 SLN, single LC/multiple SLNs (7.8%), and multiple LCs/multiple SLNs (3.9%). A total of 86.3% (44/51) of patients without axillary metastasis could be safely selected for types I, IIa, and IIb, while the axillary metastasis rates of types III and IV were 74.4% and 87.5%, respectively ( P < .001). Compared with grayscale US, the PCEUS significant improvement in diagnosing metastatic SLNs (.794 versus .579, P < .001). For the SLN metastatic burden, Types I, IIa, IIb, and IIIa had ≤2 SLNs metastases, with a pathological coincidence rate of (64/67, 95.5%), and types IIIb and IV had >2 SLNs metastases, with a pathological coincidence rate of (25/35, 71.4%) ( P < .001). The AUC of PCEUS for the diagnosis of SLN metastatic status and burden was .794 and .879, respectively ( P < .001).
Conclusion
PCEUS has a high identification rate for SLN and has good potential for diagnosing SLN metastatic status and burden by enhancement patterns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ultrasound Medical Center, Lanzhou University Second Hospital, Lanzhou, China.
- Gansu Province Clinical Research Center for Ultrasonography, Lanzhou, China.
- Critical Care Medicine, Lanzhou University Second Hospital, Lanzhou, China.
ORCID-Profile: Fang Nie
Zitieren
APA
Pang, W., Zhou, F., Zhu, Y., Jia, Y., & Nie, F. (2024). The Value of Percutaneous Contrast‐Enhanced Ultrasound in Sentinel Lymph Node Identification, Metastatic Status and Burden Diagnosis in Early Breast Cancer. Journal of Ultrasound in Medicine, 43(2), 293-303. https://doi.org/10.1002/jum.16359
Vancouver
Pang W, Zhou F, Zhu Y, Jia Y, Nie F. The Value of Percutaneous Contrast‐Enhanced Ultrasound in Sentinel Lymph Node Identification, Metastatic Status and Burden Diagnosis in Early Breast Cancer. Journal of Ultrasound in Medicine. 2024;43(2):293-303. doi:10.1002/jum.16359
BibTeX
@article{Pang2024,
author = {Pang, Wenjing and Zhou, Fei and Zhu, Yangyang and Jia, Yingying and Nie, Fang},
title = {The Value of Percutaneous Contrast‐Enhanced Ultrasound in Sentinel Lymph Node Identification, Metastatic Status and Burden Diagnosis in Early Breast Cancer},
journal = {Journal of Ultrasound in Medicine},
year = {2024},
volume = {43},
number = {2},
pages = {293--303},
doi = {10.1002/jum.16359}
}
EUVIMED